Active	Status	Sponsor type	Region	Phase	Filter
6 Active 1 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Kirschner, Janbernd
MIS51ON, NCT03992430 / 2018-001762-42: A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD)	Active, not recruiting	3	160	Europe, US, RoW	Eteplirsen, AVI-4658, EXONDYS 51, EXONDYS	Sarepta Therapeutics, Inc., Sarepta Therapeutics, Inc.	Muscular Dystrophy, Duchenne	10/26	10/26
ULYSSES, NCT05933057: Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy	Recruiting	3	138	Europe, Canada	Givinostat, ITF2357, Placebo	Italfarmaco, Fortrea	Duchenne Muscular Dystrophy	02/28	02/28
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine	Recruiting	3	1633	Europe, Japan, US, RoW	Lasmiditan, LY573144, Placebo	Eli Lilly and Company	Migraine	01/25	01/25
PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine	Recruiting	3	1000	Europe, Japan, US, RoW	Lasmiditan, LY573144	Eli Lilly and Company	Migraine	03/26	03/26